Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANGUARD: Garadacimab for HAE Prophylaxis
NCT04656418Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing CSL312 (Garadacimab) with Placebo (2 arms). Primary endpoint: Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month at 6 months. Started Jan 2021; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04656418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656418.